Global Anti-Infective Drugs

Anti-Infective Drugs Comprehensive Study by Type (Anti-bacterial Drugs, Anti-fungal Drugs, Anti-viral Drugs), Indication (Candidiasis, Aspergillosis, HIV Infection, Sepsis, Hepatitis Virus Infection, Dermatophytosis, Respiratory Virus Infection, Pneumonia, Methicillin-resistant Staphylococcus Aureus (MRSA), Tuberculosis), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Sales) Players and Region - Global Market Outlook to 2028

Anti-Infective Drugs Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Anti-Infective Drugs Market Overview:
The anti-infective drug is a medicine capable of inhibiting the spread of infectious organism or killing the infectious organism outright. Anti-infective is a general term that encompasses antibacterials, antibiotics, antifungals, antiprotozoal, and antivirals. To facilitate the translation of newly discovered compounds into the clinic, the drug delivery group is investigating strategies to improve transport across biological barriers. The demand for the anti-infective drug is expected to rise in the forecasted period owing to the rise in demand from emerging countries and drugs been widely used by the pediatric Population.

AttributesDetails
Study Period2018-2028
Base Year2022
Forecast Period2023-2028
Historical Period2018-2022
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Influencing Trend:
Development In Drug Discovery Procedures, Strategic Collaboration and Agreements and 3D Printing Technology

Market Growth Drivers:
Willingness towards Alternative Distribution and Dispensing of Antiviral Drugs, Anti-Fungal Drugs Are widely been Used by the Pediatric Population and Rising Spending in Healthcare

Challenges:
Availability of Counterfeit Products

Restraints:
Disorder in Underdeveloped and Developing Countries and Supply Shortage of Anti-infective Drugs

Opportunities:
R&D and Product Innovation, Potential Growth From Emerging Countries and Increasing Number of Pipelines Studies and Drug Development

Competitive Landscape:

Some of the key players profiled in the report are GlaxoSmithKline (United Kingdom), Merck (United States), Pfizer (United States), Novartis AG (Switzerland), Gilead Sciences (United States), Abbott (United States), Sanofi-Aventis (France), Bristol-Myers Squibb (United States), Johnson (United States), Roche Pharma AG (Switzerland), Nanosphere (United States), Optimer Pharmaceuticals (United States), Basilea Pharmaceutica AG (Switzerland), Daiichi Sankyo (Japan), NanoViricides (United States) and Novabay Pharmaceuticals (United States). Additionally, following companies can also be profiled that are part of our coverage like Obetech, MerLion Pharma and Theravance. Analyst at AMA Research see United States Players to retain maximum share of Global Anti-Infective Drugs market by 2028. Considering Market by Indication, the sub-segment i.e. Candidiasis will boost the Anti-Infective Drugs market. Considering Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacy will boost the Anti-Infective Drugs market.

According to the World Health Organization’s (WHO) report, 2018, over 30 million people worldwide are affected by sepsis that leads to 6 million deaths, annually. Moreover, over three million newborns and 1.2 million children suffer from sepsis worldwide, annually. National Institute of Allergy and Infectious Diseases (NIAID) initiated phase 2/phase 3 clinical trials to study the safety and effectiveness of four drugs including ZMapp, Remdesivir, MAb114, REGN-EB3, in people with Ebola virus infection.

What Can be Explored with the Anti-Infective Drugs Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Anti-Infective Drugs Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Anti-Infective Drugs
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Anti-Infective Drugs market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Anti-Infective Drugs market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Anti-Infective Drugs Distributors/Traders/Wholesalers, Anti-Infective Drugs Subcomponent Manufacturers, Industry Association and Downstream Vendors.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • Anti-bacterial Drugs
  • Anti-fungal Drugs
  • Anti-viral Drugs
By Indication
  • Candidiasis
  • Aspergillosis
  • HIV Infection
  • Sepsis
  • Hepatitis Virus Infection
  • Dermatophytosis
  • Respiratory Virus Infection
  • Pneumonia
  • Methicillin-resistant Staphylococcus Aureus (MRSA)
  • Tuberculosis

By Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Sales

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Willingness towards Alternative Distribution and Dispensing of Antiviral Drugs
      • 3.2.2. Anti-Fungal Drugs Are widely been Used by the Pediatric Population
      • 3.2.3. Rising Spending in Healthcare
    • 3.3. Market Challenges
      • 3.3.1. Availability of Counterfeit Products
    • 3.4. Market Trends
      • 3.4.1. Development In Drug Discovery Procedures
      • 3.4.2. Strategic Collaboration and Agreements
      • 3.4.3. 3D Printing Technology
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Anti-Infective Drugs, by Type, Indication, Distribution Channel and Region (value, volume and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Anti-Infective Drugs (Value)
      • 5.2.1. Global Anti-Infective Drugs by: Type (Value)
        • 5.2.1.1. Anti-bacterial Drugs
        • 5.2.1.2. Anti-fungal Drugs
        • 5.2.1.3. Anti-viral Drugs
      • 5.2.2. Global Anti-Infective Drugs by: Indication (Value)
        • 5.2.2.1. Candidiasis
        • 5.2.2.2. Aspergillosis
        • 5.2.2.3. HIV Infection
        • 5.2.2.4. Sepsis
        • 5.2.2.5. Hepatitis Virus Infection
        • 5.2.2.6. Dermatophytosis
        • 5.2.2.7. Respiratory Virus Infection
        • 5.2.2.8. Pneumonia
        • 5.2.2.9. Methicillin-resistant Staphylococcus Aureus (MRSA)
        • 5.2.2.10. Tuberculosis
      • 5.2.3. Global Anti-Infective Drugs by: Distribution Channel (Value)
        • 5.2.3.1. Hospital Pharmacy
        • 5.2.3.2. Retail Pharmacy
        • 5.2.3.3. Online Sales
      • 5.2.4. Global Anti-Infective Drugs Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Anti-Infective Drugs (Volume)
      • 5.3.1. Global Anti-Infective Drugs by: Type (Volume)
        • 5.3.1.1. Anti-bacterial Drugs
        • 5.3.1.2. Anti-fungal Drugs
        • 5.3.1.3. Anti-viral Drugs
      • 5.3.2. Global Anti-Infective Drugs by: Indication (Volume)
        • 5.3.2.1. Candidiasis
        • 5.3.2.2. Aspergillosis
        • 5.3.2.3. HIV Infection
        • 5.3.2.4. Sepsis
        • 5.3.2.5. Hepatitis Virus Infection
        • 5.3.2.6. Dermatophytosis
        • 5.3.2.7. Respiratory Virus Infection
        • 5.3.2.8. Pneumonia
        • 5.3.2.9. Methicillin-resistant Staphylococcus Aureus (MRSA)
        • 5.3.2.10. Tuberculosis
      • 5.3.3. Global Anti-Infective Drugs by: Distribution Channel (Volume)
        • 5.3.3.1. Hospital Pharmacy
        • 5.3.3.2. Retail Pharmacy
        • 5.3.3.3. Online Sales
      • 5.3.4. Global Anti-Infective Drugs Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Anti-Infective Drugs (Price)
      • 5.4.1. Global Anti-Infective Drugs by: Type (Price)
  • 6. Anti-Infective Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GlaxoSmithKline (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Merck (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Pfizer (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Novartis AG (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Gilead Sciences (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Abbott (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Sanofi-Aventis (France)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Bristol-Myers Squibb (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Johnson (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Roche Pharma AG (Switzerland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Nanosphere (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Optimer Pharmaceuticals (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Basilea Pharmaceutica AG (Switzerland)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. Daiichi Sankyo (Japan)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
      • 6.4.15. NanoViricides (United States)
        • 6.4.15.1. Business Overview
        • 6.4.15.2. Products/Services Offerings
        • 6.4.15.3. Financial Analysis
        • 6.4.15.4. SWOT Analysis
      • 6.4.16. Novabay Pharmaceuticals (United States)
        • 6.4.16.1. Business Overview
        • 6.4.16.2. Products/Services Offerings
        • 6.4.16.3. Financial Analysis
        • 6.4.16.4. SWOT Analysis
  • 7. Global Anti-Infective Drugs Sale, by Type, Indication, Distribution Channel and Region (value, volume and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Anti-Infective Drugs (Value)
      • 7.2.1. Global Anti-Infective Drugs by: Type (Value)
        • 7.2.1.1. Anti-bacterial Drugs
        • 7.2.1.2. Anti-fungal Drugs
        • 7.2.1.3. Anti-viral Drugs
      • 7.2.2. Global Anti-Infective Drugs by: Indication (Value)
        • 7.2.2.1. Candidiasis
        • 7.2.2.2. Aspergillosis
        • 7.2.2.3. HIV Infection
        • 7.2.2.4. Sepsis
        • 7.2.2.5. Hepatitis Virus Infection
        • 7.2.2.6. Dermatophytosis
        • 7.2.2.7. Respiratory Virus Infection
        • 7.2.2.8. Pneumonia
        • 7.2.2.9. Methicillin-resistant Staphylococcus Aureus (MRSA)
        • 7.2.2.10. Tuberculosis
      • 7.2.3. Global Anti-Infective Drugs by: Distribution Channel (Value)
        • 7.2.3.1. Hospital Pharmacy
        • 7.2.3.2. Retail Pharmacy
        • 7.2.3.3. Online Sales
      • 7.2.4. Global Anti-Infective Drugs Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Anti-Infective Drugs (Volume)
      • 7.3.1. Global Anti-Infective Drugs by: Type (Volume)
        • 7.3.1.1. Anti-bacterial Drugs
        • 7.3.1.2. Anti-fungal Drugs
        • 7.3.1.3. Anti-viral Drugs
      • 7.3.2. Global Anti-Infective Drugs by: Indication (Volume)
        • 7.3.2.1. Candidiasis
        • 7.3.2.2. Aspergillosis
        • 7.3.2.3. HIV Infection
        • 7.3.2.4. Sepsis
        • 7.3.2.5. Hepatitis Virus Infection
        • 7.3.2.6. Dermatophytosis
        • 7.3.2.7. Respiratory Virus Infection
        • 7.3.2.8. Pneumonia
        • 7.3.2.9. Methicillin-resistant Staphylococcus Aureus (MRSA)
        • 7.3.2.10. Tuberculosis
      • 7.3.3. Global Anti-Infective Drugs by: Distribution Channel (Volume)
        • 7.3.3.1. Hospital Pharmacy
        • 7.3.3.2. Retail Pharmacy
        • 7.3.3.3. Online Sales
      • 7.3.4. Global Anti-Infective Drugs Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Anti-Infective Drugs (Price)
      • 7.4.1. Global Anti-Infective Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Anti-Infective Drugs: by Type(USD Million)
  • Table 2. Anti-Infective Drugs Anti-bacterial Drugs , by Region USD Million (2017-2022)
  • Table 3. Anti-Infective Drugs Anti-fungal Drugs , by Region USD Million (2017-2022)
  • Table 4. Anti-Infective Drugs Anti-viral Drugs , by Region USD Million (2017-2022)
  • Table 5. Anti-Infective Drugs: by Indication(USD Million)
  • Table 6. Anti-Infective Drugs Candidiasis , by Region USD Million (2017-2022)
  • Table 7. Anti-Infective Drugs Aspergillosis , by Region USD Million (2017-2022)
  • Table 8. Anti-Infective Drugs HIV Infection , by Region USD Million (2017-2022)
  • Table 9. Anti-Infective Drugs Sepsis , by Region USD Million (2017-2022)
  • Table 10. Anti-Infective Drugs Hepatitis Virus Infection , by Region USD Million (2017-2022)
  • Table 11. Anti-Infective Drugs Dermatophytosis , by Region USD Million (2017-2022)
  • Table 12. Anti-Infective Drugs Respiratory Virus Infection , by Region USD Million (2017-2022)
  • Table 13. Anti-Infective Drugs Pneumonia , by Region USD Million (2017-2022)
  • Table 14. Anti-Infective Drugs Methicillin-resistant Staphylococcus Aureus (MRSA) , by Region USD Million (2017-2022)
  • Table 15. Anti-Infective Drugs Tuberculosis , by Region USD Million (2017-2022)
  • Table 16. Anti-Infective Drugs: by Distribution Channel(USD Million)
  • Table 17. Anti-Infective Drugs Hospital Pharmacy , by Region USD Million (2017-2022)
  • Table 18. Anti-Infective Drugs Retail Pharmacy , by Region USD Million (2017-2022)
  • Table 19. Anti-Infective Drugs Online Sales , by Region USD Million (2017-2022)
  • Table 20. South America Anti-Infective Drugs, by Country USD Million (2017-2022)
  • Table 21. South America Anti-Infective Drugs, by Type USD Million (2017-2022)
  • Table 22. South America Anti-Infective Drugs, by Indication USD Million (2017-2022)
  • Table 23. South America Anti-Infective Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 24. Brazil Anti-Infective Drugs, by Type USD Million (2017-2022)
  • Table 25. Brazil Anti-Infective Drugs, by Indication USD Million (2017-2022)
  • Table 26. Brazil Anti-Infective Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 27. Argentina Anti-Infective Drugs, by Type USD Million (2017-2022)
  • Table 28. Argentina Anti-Infective Drugs, by Indication USD Million (2017-2022)
  • Table 29. Argentina Anti-Infective Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 30. Rest of South America Anti-Infective Drugs, by Type USD Million (2017-2022)
  • Table 31. Rest of South America Anti-Infective Drugs, by Indication USD Million (2017-2022)
  • Table 32. Rest of South America Anti-Infective Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 33. Asia Pacific Anti-Infective Drugs, by Country USD Million (2017-2022)
  • Table 34. Asia Pacific Anti-Infective Drugs, by Type USD Million (2017-2022)
  • Table 35. Asia Pacific Anti-Infective Drugs, by Indication USD Million (2017-2022)
  • Table 36. Asia Pacific Anti-Infective Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 37. China Anti-Infective Drugs, by Type USD Million (2017-2022)
  • Table 38. China Anti-Infective Drugs, by Indication USD Million (2017-2022)
  • Table 39. China Anti-Infective Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 40. Japan Anti-Infective Drugs, by Type USD Million (2017-2022)
  • Table 41. Japan Anti-Infective Drugs, by Indication USD Million (2017-2022)
  • Table 42. Japan Anti-Infective Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 43. India Anti-Infective Drugs, by Type USD Million (2017-2022)
  • Table 44. India Anti-Infective Drugs, by Indication USD Million (2017-2022)
  • Table 45. India Anti-Infective Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 46. South Korea Anti-Infective Drugs, by Type USD Million (2017-2022)
  • Table 47. South Korea Anti-Infective Drugs, by Indication USD Million (2017-2022)
  • Table 48. South Korea Anti-Infective Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 49. Taiwan Anti-Infective Drugs, by Type USD Million (2017-2022)
  • Table 50. Taiwan Anti-Infective Drugs, by Indication USD Million (2017-2022)
  • Table 51. Taiwan Anti-Infective Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 52. Australia Anti-Infective Drugs, by Type USD Million (2017-2022)
  • Table 53. Australia Anti-Infective Drugs, by Indication USD Million (2017-2022)
  • Table 54. Australia Anti-Infective Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 55. Rest of Asia-Pacific Anti-Infective Drugs, by Type USD Million (2017-2022)
  • Table 56. Rest of Asia-Pacific Anti-Infective Drugs, by Indication USD Million (2017-2022)
  • Table 57. Rest of Asia-Pacific Anti-Infective Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 58. Europe Anti-Infective Drugs, by Country USD Million (2017-2022)
  • Table 59. Europe Anti-Infective Drugs, by Type USD Million (2017-2022)
  • Table 60. Europe Anti-Infective Drugs, by Indication USD Million (2017-2022)
  • Table 61. Europe Anti-Infective Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 62. Germany Anti-Infective Drugs, by Type USD Million (2017-2022)
  • Table 63. Germany Anti-Infective Drugs, by Indication USD Million (2017-2022)
  • Table 64. Germany Anti-Infective Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 65. France Anti-Infective Drugs, by Type USD Million (2017-2022)
  • Table 66. France Anti-Infective Drugs, by Indication USD Million (2017-2022)
  • Table 67. France Anti-Infective Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 68. Italy Anti-Infective Drugs, by Type USD Million (2017-2022)
  • Table 69. Italy Anti-Infective Drugs, by Indication USD Million (2017-2022)
  • Table 70. Italy Anti-Infective Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 71. United Kingdom Anti-Infective Drugs, by Type USD Million (2017-2022)
  • Table 72. United Kingdom Anti-Infective Drugs, by Indication USD Million (2017-2022)
  • Table 73. United Kingdom Anti-Infective Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 74. Netherlands Anti-Infective Drugs, by Type USD Million (2017-2022)
  • Table 75. Netherlands Anti-Infective Drugs, by Indication USD Million (2017-2022)
  • Table 76. Netherlands Anti-Infective Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 77. Rest of Europe Anti-Infective Drugs, by Type USD Million (2017-2022)
  • Table 78. Rest of Europe Anti-Infective Drugs, by Indication USD Million (2017-2022)
  • Table 79. Rest of Europe Anti-Infective Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 80. MEA Anti-Infective Drugs, by Country USD Million (2017-2022)
  • Table 81. MEA Anti-Infective Drugs, by Type USD Million (2017-2022)
  • Table 82. MEA Anti-Infective Drugs, by Indication USD Million (2017-2022)
  • Table 83. MEA Anti-Infective Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 84. Middle East Anti-Infective Drugs, by Type USD Million (2017-2022)
  • Table 85. Middle East Anti-Infective Drugs, by Indication USD Million (2017-2022)
  • Table 86. Middle East Anti-Infective Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 87. Africa Anti-Infective Drugs, by Type USD Million (2017-2022)
  • Table 88. Africa Anti-Infective Drugs, by Indication USD Million (2017-2022)
  • Table 89. Africa Anti-Infective Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 90. North America Anti-Infective Drugs, by Country USD Million (2017-2022)
  • Table 91. North America Anti-Infective Drugs, by Type USD Million (2017-2022)
  • Table 92. North America Anti-Infective Drugs, by Indication USD Million (2017-2022)
  • Table 93. North America Anti-Infective Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 94. United States Anti-Infective Drugs, by Type USD Million (2017-2022)
  • Table 95. United States Anti-Infective Drugs, by Indication USD Million (2017-2022)
  • Table 96. United States Anti-Infective Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 97. Canada Anti-Infective Drugs, by Type USD Million (2017-2022)
  • Table 98. Canada Anti-Infective Drugs, by Indication USD Million (2017-2022)
  • Table 99. Canada Anti-Infective Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 100. Mexico Anti-Infective Drugs, by Type USD Million (2017-2022)
  • Table 101. Mexico Anti-Infective Drugs, by Indication USD Million (2017-2022)
  • Table 102. Mexico Anti-Infective Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 103. Anti-Infective Drugs Sales: by Type(K Unit)
  • Table 104. Anti-Infective Drugs Sales Anti-bacterial Drugs , by Region K Unit (2017-2022)
  • Table 105. Anti-Infective Drugs Sales Anti-fungal Drugs , by Region K Unit (2017-2022)
  • Table 106. Anti-Infective Drugs Sales Anti-viral Drugs , by Region K Unit (2017-2022)
  • Table 107. Anti-Infective Drugs Sales: by Indication(K Unit)
  • Table 108. Anti-Infective Drugs Sales Candidiasis , by Region K Unit (2017-2022)
  • Table 109. Anti-Infective Drugs Sales Aspergillosis , by Region K Unit (2017-2022)
  • Table 110. Anti-Infective Drugs Sales HIV Infection , by Region K Unit (2017-2022)
  • Table 111. Anti-Infective Drugs Sales Sepsis , by Region K Unit (2017-2022)
  • Table 112. Anti-Infective Drugs Sales Hepatitis Virus Infection , by Region K Unit (2017-2022)
  • Table 113. Anti-Infective Drugs Sales Dermatophytosis , by Region K Unit (2017-2022)
  • Table 114. Anti-Infective Drugs Sales Respiratory Virus Infection , by Region K Unit (2017-2022)
  • Table 115. Anti-Infective Drugs Sales Pneumonia , by Region K Unit (2017-2022)
  • Table 116. Anti-Infective Drugs Sales Methicillin-resistant Staphylococcus Aureus (MRSA) , by Region K Unit (2017-2022)
  • Table 117. Anti-Infective Drugs Sales Tuberculosis , by Region K Unit (2017-2022)
  • Table 118. Anti-Infective Drugs Sales: by Distribution Channel(K Unit)
  • Table 119. Anti-Infective Drugs Sales Hospital Pharmacy , by Region K Unit (2017-2022)
  • Table 120. Anti-Infective Drugs Sales Retail Pharmacy , by Region K Unit (2017-2022)
  • Table 121. Anti-Infective Drugs Sales Online Sales , by Region K Unit (2017-2022)
  • Table 122. South America Anti-Infective Drugs Sales, by Country K Unit (2017-2022)
  • Table 123. South America Anti-Infective Drugs Sales, by Type K Unit (2017-2022)
  • Table 124. South America Anti-Infective Drugs Sales, by Indication K Unit (2017-2022)
  • Table 125. South America Anti-Infective Drugs Sales, by Distribution Channel K Unit (2017-2022)
  • Table 126. Brazil Anti-Infective Drugs Sales, by Type K Unit (2017-2022)
  • Table 127. Brazil Anti-Infective Drugs Sales, by Indication K Unit (2017-2022)
  • Table 128. Brazil Anti-Infective Drugs Sales, by Distribution Channel K Unit (2017-2022)
  • Table 129. Argentina Anti-Infective Drugs Sales, by Type K Unit (2017-2022)
  • Table 130. Argentina Anti-Infective Drugs Sales, by Indication K Unit (2017-2022)
  • Table 131. Argentina Anti-Infective Drugs Sales, by Distribution Channel K Unit (2017-2022)
  • Table 132. Rest of South America Anti-Infective Drugs Sales, by Type K Unit (2017-2022)
  • Table 133. Rest of South America Anti-Infective Drugs Sales, by Indication K Unit (2017-2022)
  • Table 134. Rest of South America Anti-Infective Drugs Sales, by Distribution Channel K Unit (2017-2022)
  • Table 135. Asia Pacific Anti-Infective Drugs Sales, by Country K Unit (2017-2022)
  • Table 136. Asia Pacific Anti-Infective Drugs Sales, by Type K Unit (2017-2022)
  • Table 137. Asia Pacific Anti-Infective Drugs Sales, by Indication K Unit (2017-2022)
  • Table 138. Asia Pacific Anti-Infective Drugs Sales, by Distribution Channel K Unit (2017-2022)
  • Table 139. China Anti-Infective Drugs Sales, by Type K Unit (2017-2022)
  • Table 140. China Anti-Infective Drugs Sales, by Indication K Unit (2017-2022)
  • Table 141. China Anti-Infective Drugs Sales, by Distribution Channel K Unit (2017-2022)
  • Table 142. Japan Anti-Infective Drugs Sales, by Type K Unit (2017-2022)
  • Table 143. Japan Anti-Infective Drugs Sales, by Indication K Unit (2017-2022)
  • Table 144. Japan Anti-Infective Drugs Sales, by Distribution Channel K Unit (2017-2022)
  • Table 145. India Anti-Infective Drugs Sales, by Type K Unit (2017-2022)
  • Table 146. India Anti-Infective Drugs Sales, by Indication K Unit (2017-2022)
  • Table 147. India Anti-Infective Drugs Sales, by Distribution Channel K Unit (2017-2022)
  • Table 148. South Korea Anti-Infective Drugs Sales, by Type K Unit (2017-2022)
  • Table 149. South Korea Anti-Infective Drugs Sales, by Indication K Unit (2017-2022)
  • Table 150. South Korea Anti-Infective Drugs Sales, by Distribution Channel K Unit (2017-2022)
  • Table 151. Taiwan Anti-Infective Drugs Sales, by Type K Unit (2017-2022)
  • Table 152. Taiwan Anti-Infective Drugs Sales, by Indication K Unit (2017-2022)
  • Table 153. Taiwan Anti-Infective Drugs Sales, by Distribution Channel K Unit (2017-2022)
  • Table 154. Australia Anti-Infective Drugs Sales, by Type K Unit (2017-2022)
  • Table 155. Australia Anti-Infective Drugs Sales, by Indication K Unit (2017-2022)
  • Table 156. Australia Anti-Infective Drugs Sales, by Distribution Channel K Unit (2017-2022)
  • Table 157. Rest of Asia-Pacific Anti-Infective Drugs Sales, by Type K Unit (2017-2022)
  • Table 158. Rest of Asia-Pacific Anti-Infective Drugs Sales, by Indication K Unit (2017-2022)
  • Table 159. Rest of Asia-Pacific Anti-Infective Drugs Sales, by Distribution Channel K Unit (2017-2022)
  • Table 160. Europe Anti-Infective Drugs Sales, by Country K Unit (2017-2022)
  • Table 161. Europe Anti-Infective Drugs Sales, by Type K Unit (2017-2022)
  • Table 162. Europe Anti-Infective Drugs Sales, by Indication K Unit (2017-2022)
  • Table 163. Europe Anti-Infective Drugs Sales, by Distribution Channel K Unit (2017-2022)
  • Table 164. Germany Anti-Infective Drugs Sales, by Type K Unit (2017-2022)
  • Table 165. Germany Anti-Infective Drugs Sales, by Indication K Unit (2017-2022)
  • Table 166. Germany Anti-Infective Drugs Sales, by Distribution Channel K Unit (2017-2022)
  • Table 167. France Anti-Infective Drugs Sales, by Type K Unit (2017-2022)
  • Table 168. France Anti-Infective Drugs Sales, by Indication K Unit (2017-2022)
  • Table 169. France Anti-Infective Drugs Sales, by Distribution Channel K Unit (2017-2022)
  • Table 170. Italy Anti-Infective Drugs Sales, by Type K Unit (2017-2022)
  • Table 171. Italy Anti-Infective Drugs Sales, by Indication K Unit (2017-2022)
  • Table 172. Italy Anti-Infective Drugs Sales, by Distribution Channel K Unit (2017-2022)
  • Table 173. United Kingdom Anti-Infective Drugs Sales, by Type K Unit (2017-2022)
  • Table 174. United Kingdom Anti-Infective Drugs Sales, by Indication K Unit (2017-2022)
  • Table 175. United Kingdom Anti-Infective Drugs Sales, by Distribution Channel K Unit (2017-2022)
  • Table 176. Netherlands Anti-Infective Drugs Sales, by Type K Unit (2017-2022)
  • Table 177. Netherlands Anti-Infective Drugs Sales, by Indication K Unit (2017-2022)
  • Table 178. Netherlands Anti-Infective Drugs Sales, by Distribution Channel K Unit (2017-2022)
  • Table 179. Rest of Europe Anti-Infective Drugs Sales, by Type K Unit (2017-2022)
  • Table 180. Rest of Europe Anti-Infective Drugs Sales, by Indication K Unit (2017-2022)
  • Table 181. Rest of Europe Anti-Infective Drugs Sales, by Distribution Channel K Unit (2017-2022)
  • Table 182. MEA Anti-Infective Drugs Sales, by Country K Unit (2017-2022)
  • Table 183. MEA Anti-Infective Drugs Sales, by Type K Unit (2017-2022)
  • Table 184. MEA Anti-Infective Drugs Sales, by Indication K Unit (2017-2022)
  • Table 185. MEA Anti-Infective Drugs Sales, by Distribution Channel K Unit (2017-2022)
  • Table 186. Middle East Anti-Infective Drugs Sales, by Type K Unit (2017-2022)
  • Table 187. Middle East Anti-Infective Drugs Sales, by Indication K Unit (2017-2022)
  • Table 188. Middle East Anti-Infective Drugs Sales, by Distribution Channel K Unit (2017-2022)
  • Table 189. Africa Anti-Infective Drugs Sales, by Type K Unit (2017-2022)
  • Table 190. Africa Anti-Infective Drugs Sales, by Indication K Unit (2017-2022)
  • Table 191. Africa Anti-Infective Drugs Sales, by Distribution Channel K Unit (2017-2022)
  • Table 192. North America Anti-Infective Drugs Sales, by Country K Unit (2017-2022)
  • Table 193. North America Anti-Infective Drugs Sales, by Type K Unit (2017-2022)
  • Table 194. North America Anti-Infective Drugs Sales, by Indication K Unit (2017-2022)
  • Table 195. North America Anti-Infective Drugs Sales, by Distribution Channel K Unit (2017-2022)
  • Table 196. United States Anti-Infective Drugs Sales, by Type K Unit (2017-2022)
  • Table 197. United States Anti-Infective Drugs Sales, by Indication K Unit (2017-2022)
  • Table 198. United States Anti-Infective Drugs Sales, by Distribution Channel K Unit (2017-2022)
  • Table 199. Canada Anti-Infective Drugs Sales, by Type K Unit (2017-2022)
  • Table 200. Canada Anti-Infective Drugs Sales, by Indication K Unit (2017-2022)
  • Table 201. Canada Anti-Infective Drugs Sales, by Distribution Channel K Unit (2017-2022)
  • Table 202. Mexico Anti-Infective Drugs Sales, by Type K Unit (2017-2022)
  • Table 203. Mexico Anti-Infective Drugs Sales, by Indication K Unit (2017-2022)
  • Table 204. Mexico Anti-Infective Drugs Sales, by Distribution Channel K Unit (2017-2022)
  • Table 205. Anti-Infective Drugs: by Type(USD/Units)
  • Table 206. Company Basic Information, Sales Area and Its Competitors
  • Table 207. Company Basic Information, Sales Area and Its Competitors
  • Table 208. Company Basic Information, Sales Area and Its Competitors
  • Table 209. Company Basic Information, Sales Area and Its Competitors
  • Table 210. Company Basic Information, Sales Area and Its Competitors
  • Table 211. Company Basic Information, Sales Area and Its Competitors
  • Table 212. Company Basic Information, Sales Area and Its Competitors
  • Table 213. Company Basic Information, Sales Area and Its Competitors
  • Table 214. Company Basic Information, Sales Area and Its Competitors
  • Table 215. Company Basic Information, Sales Area and Its Competitors
  • Table 216. Company Basic Information, Sales Area and Its Competitors
  • Table 217. Company Basic Information, Sales Area and Its Competitors
  • Table 218. Company Basic Information, Sales Area and Its Competitors
  • Table 219. Company Basic Information, Sales Area and Its Competitors
  • Table 220. Company Basic Information, Sales Area and Its Competitors
  • Table 221. Company Basic Information, Sales Area and Its Competitors
  • Table 222. Anti-Infective Drugs: by Type(USD Million)
  • Table 223. Anti-Infective Drugs Anti-bacterial Drugs , by Region USD Million (2023-2028)
  • Table 224. Anti-Infective Drugs Anti-fungal Drugs , by Region USD Million (2023-2028)
  • Table 225. Anti-Infective Drugs Anti-viral Drugs , by Region USD Million (2023-2028)
  • Table 226. Anti-Infective Drugs: by Indication(USD Million)
  • Table 227. Anti-Infective Drugs Candidiasis , by Region USD Million (2023-2028)
  • Table 228. Anti-Infective Drugs Aspergillosis , by Region USD Million (2023-2028)
  • Table 229. Anti-Infective Drugs HIV Infection , by Region USD Million (2023-2028)
  • Table 230. Anti-Infective Drugs Sepsis , by Region USD Million (2023-2028)
  • Table 231. Anti-Infective Drugs Hepatitis Virus Infection , by Region USD Million (2023-2028)
  • Table 232. Anti-Infective Drugs Dermatophytosis , by Region USD Million (2023-2028)
  • Table 233. Anti-Infective Drugs Respiratory Virus Infection , by Region USD Million (2023-2028)
  • Table 234. Anti-Infective Drugs Pneumonia , by Region USD Million (2023-2028)
  • Table 235. Anti-Infective Drugs Methicillin-resistant Staphylococcus Aureus (MRSA) , by Region USD Million (2023-2028)
  • Table 236. Anti-Infective Drugs Tuberculosis , by Region USD Million (2023-2028)
  • Table 237. Anti-Infective Drugs: by Distribution Channel(USD Million)
  • Table 238. Anti-Infective Drugs Hospital Pharmacy , by Region USD Million (2023-2028)
  • Table 239. Anti-Infective Drugs Retail Pharmacy , by Region USD Million (2023-2028)
  • Table 240. Anti-Infective Drugs Online Sales , by Region USD Million (2023-2028)
  • Table 241. South America Anti-Infective Drugs, by Country USD Million (2023-2028)
  • Table 242. South America Anti-Infective Drugs, by Type USD Million (2023-2028)
  • Table 243. South America Anti-Infective Drugs, by Indication USD Million (2023-2028)
  • Table 244. South America Anti-Infective Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 245. Brazil Anti-Infective Drugs, by Type USD Million (2023-2028)
  • Table 246. Brazil Anti-Infective Drugs, by Indication USD Million (2023-2028)
  • Table 247. Brazil Anti-Infective Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 248. Argentina Anti-Infective Drugs, by Type USD Million (2023-2028)
  • Table 249. Argentina Anti-Infective Drugs, by Indication USD Million (2023-2028)
  • Table 250. Argentina Anti-Infective Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 251. Rest of South America Anti-Infective Drugs, by Type USD Million (2023-2028)
  • Table 252. Rest of South America Anti-Infective Drugs, by Indication USD Million (2023-2028)
  • Table 253. Rest of South America Anti-Infective Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 254. Asia Pacific Anti-Infective Drugs, by Country USD Million (2023-2028)
  • Table 255. Asia Pacific Anti-Infective Drugs, by Type USD Million (2023-2028)
  • Table 256. Asia Pacific Anti-Infective Drugs, by Indication USD Million (2023-2028)
  • Table 257. Asia Pacific Anti-Infective Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 258. China Anti-Infective Drugs, by Type USD Million (2023-2028)
  • Table 259. China Anti-Infective Drugs, by Indication USD Million (2023-2028)
  • Table 260. China Anti-Infective Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 261. Japan Anti-Infective Drugs, by Type USD Million (2023-2028)
  • Table 262. Japan Anti-Infective Drugs, by Indication USD Million (2023-2028)
  • Table 263. Japan Anti-Infective Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 264. India Anti-Infective Drugs, by Type USD Million (2023-2028)
  • Table 265. India Anti-Infective Drugs, by Indication USD Million (2023-2028)
  • Table 266. India Anti-Infective Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 267. South Korea Anti-Infective Drugs, by Type USD Million (2023-2028)
  • Table 268. South Korea Anti-Infective Drugs, by Indication USD Million (2023-2028)
  • Table 269. South Korea Anti-Infective Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 270. Taiwan Anti-Infective Drugs, by Type USD Million (2023-2028)
  • Table 271. Taiwan Anti-Infective Drugs, by Indication USD Million (2023-2028)
  • Table 272. Taiwan Anti-Infective Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 273. Australia Anti-Infective Drugs, by Type USD Million (2023-2028)
  • Table 274. Australia Anti-Infective Drugs, by Indication USD Million (2023-2028)
  • Table 275. Australia Anti-Infective Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 276. Rest of Asia-Pacific Anti-Infective Drugs, by Type USD Million (2023-2028)
  • Table 277. Rest of Asia-Pacific Anti-Infective Drugs, by Indication USD Million (2023-2028)
  • Table 278. Rest of Asia-Pacific Anti-Infective Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 279. Europe Anti-Infective Drugs, by Country USD Million (2023-2028)
  • Table 280. Europe Anti-Infective Drugs, by Type USD Million (2023-2028)
  • Table 281. Europe Anti-Infective Drugs, by Indication USD Million (2023-2028)
  • Table 282. Europe Anti-Infective Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 283. Germany Anti-Infective Drugs, by Type USD Million (2023-2028)
  • Table 284. Germany Anti-Infective Drugs, by Indication USD Million (2023-2028)
  • Table 285. Germany Anti-Infective Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 286. France Anti-Infective Drugs, by Type USD Million (2023-2028)
  • Table 287. France Anti-Infective Drugs, by Indication USD Million (2023-2028)
  • Table 288. France Anti-Infective Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 289. Italy Anti-Infective Drugs, by Type USD Million (2023-2028)
  • Table 290. Italy Anti-Infective Drugs, by Indication USD Million (2023-2028)
  • Table 291. Italy Anti-Infective Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 292. United Kingdom Anti-Infective Drugs, by Type USD Million (2023-2028)
  • Table 293. United Kingdom Anti-Infective Drugs, by Indication USD Million (2023-2028)
  • Table 294. United Kingdom Anti-Infective Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 295. Netherlands Anti-Infective Drugs, by Type USD Million (2023-2028)
  • Table 296. Netherlands Anti-Infective Drugs, by Indication USD Million (2023-2028)
  • Table 297. Netherlands Anti-Infective Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 298. Rest of Europe Anti-Infective Drugs, by Type USD Million (2023-2028)
  • Table 299. Rest of Europe Anti-Infective Drugs, by Indication USD Million (2023-2028)
  • Table 300. Rest of Europe Anti-Infective Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 301. MEA Anti-Infective Drugs, by Country USD Million (2023-2028)
  • Table 302. MEA Anti-Infective Drugs, by Type USD Million (2023-2028)
  • Table 303. MEA Anti-Infective Drugs, by Indication USD Million (2023-2028)
  • Table 304. MEA Anti-Infective Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 305. Middle East Anti-Infective Drugs, by Type USD Million (2023-2028)
  • Table 306. Middle East Anti-Infective Drugs, by Indication USD Million (2023-2028)
  • Table 307. Middle East Anti-Infective Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 308. Africa Anti-Infective Drugs, by Type USD Million (2023-2028)
  • Table 309. Africa Anti-Infective Drugs, by Indication USD Million (2023-2028)
  • Table 310. Africa Anti-Infective Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 311. North America Anti-Infective Drugs, by Country USD Million (2023-2028)
  • Table 312. North America Anti-Infective Drugs, by Type USD Million (2023-2028)
  • Table 313. North America Anti-Infective Drugs, by Indication USD Million (2023-2028)
  • Table 314. North America Anti-Infective Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 315. United States Anti-Infective Drugs, by Type USD Million (2023-2028)
  • Table 316. United States Anti-Infective Drugs, by Indication USD Million (2023-2028)
  • Table 317. United States Anti-Infective Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 318. Canada Anti-Infective Drugs, by Type USD Million (2023-2028)
  • Table 319. Canada Anti-Infective Drugs, by Indication USD Million (2023-2028)
  • Table 320. Canada Anti-Infective Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 321. Mexico Anti-Infective Drugs, by Type USD Million (2023-2028)
  • Table 322. Mexico Anti-Infective Drugs, by Indication USD Million (2023-2028)
  • Table 323. Mexico Anti-Infective Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 324. Anti-Infective Drugs Sales: by Type(K Unit)
  • Table 325. Anti-Infective Drugs Sales Anti-bacterial Drugs , by Region K Unit (2023-2028)
  • Table 326. Anti-Infective Drugs Sales Anti-fungal Drugs , by Region K Unit (2023-2028)
  • Table 327. Anti-Infective Drugs Sales Anti-viral Drugs , by Region K Unit (2023-2028)
  • Table 328. Anti-Infective Drugs Sales: by Indication(K Unit)
  • Table 329. Anti-Infective Drugs Sales Candidiasis , by Region K Unit (2023-2028)
  • Table 330. Anti-Infective Drugs Sales Aspergillosis , by Region K Unit (2023-2028)
  • Table 331. Anti-Infective Drugs Sales HIV Infection , by Region K Unit (2023-2028)
  • Table 332. Anti-Infective Drugs Sales Sepsis , by Region K Unit (2023-2028)
  • Table 333. Anti-Infective Drugs Sales Hepatitis Virus Infection , by Region K Unit (2023-2028)
  • Table 334. Anti-Infective Drugs Sales Dermatophytosis , by Region K Unit (2023-2028)
  • Table 335. Anti-Infective Drugs Sales Respiratory Virus Infection , by Region K Unit (2023-2028)
  • Table 336. Anti-Infective Drugs Sales Pneumonia , by Region K Unit (2023-2028)
  • Table 337. Anti-Infective Drugs Sales Methicillin-resistant Staphylococcus Aureus (MRSA) , by Region K Unit (2023-2028)
  • Table 338. Anti-Infective Drugs Sales Tuberculosis , by Region K Unit (2023-2028)
  • Table 339. Anti-Infective Drugs Sales: by Distribution Channel(K Unit)
  • Table 340. Anti-Infective Drugs Sales Hospital Pharmacy , by Region K Unit (2023-2028)
  • Table 341. Anti-Infective Drugs Sales Retail Pharmacy , by Region K Unit (2023-2028)
  • Table 342. Anti-Infective Drugs Sales Online Sales , by Region K Unit (2023-2028)
  • Table 343. South America Anti-Infective Drugs Sales, by Country K Unit (2023-2028)
  • Table 344. South America Anti-Infective Drugs Sales, by Type K Unit (2023-2028)
  • Table 345. South America Anti-Infective Drugs Sales, by Indication K Unit (2023-2028)
  • Table 346. South America Anti-Infective Drugs Sales, by Distribution Channel K Unit (2023-2028)
  • Table 347. Brazil Anti-Infective Drugs Sales, by Type K Unit (2023-2028)
  • Table 348. Brazil Anti-Infective Drugs Sales, by Indication K Unit (2023-2028)
  • Table 349. Brazil Anti-Infective Drugs Sales, by Distribution Channel K Unit (2023-2028)
  • Table 350. Argentina Anti-Infective Drugs Sales, by Type K Unit (2023-2028)
  • Table 351. Argentina Anti-Infective Drugs Sales, by Indication K Unit (2023-2028)
  • Table 352. Argentina Anti-Infective Drugs Sales, by Distribution Channel K Unit (2023-2028)
  • Table 353. Rest of South America Anti-Infective Drugs Sales, by Type K Unit (2023-2028)
  • Table 354. Rest of South America Anti-Infective Drugs Sales, by Indication K Unit (2023-2028)
  • Table 355. Rest of South America Anti-Infective Drugs Sales, by Distribution Channel K Unit (2023-2028)
  • Table 356. Asia Pacific Anti-Infective Drugs Sales, by Country K Unit (2023-2028)
  • Table 357. Asia Pacific Anti-Infective Drugs Sales, by Type K Unit (2023-2028)
  • Table 358. Asia Pacific Anti-Infective Drugs Sales, by Indication K Unit (2023-2028)
  • Table 359. Asia Pacific Anti-Infective Drugs Sales, by Distribution Channel K Unit (2023-2028)
  • Table 360. China Anti-Infective Drugs Sales, by Type K Unit (2023-2028)
  • Table 361. China Anti-Infective Drugs Sales, by Indication K Unit (2023-2028)
  • Table 362. China Anti-Infective Drugs Sales, by Distribution Channel K Unit (2023-2028)
  • Table 363. Japan Anti-Infective Drugs Sales, by Type K Unit (2023-2028)
  • Table 364. Japan Anti-Infective Drugs Sales, by Indication K Unit (2023-2028)
  • Table 365. Japan Anti-Infective Drugs Sales, by Distribution Channel K Unit (2023-2028)
  • Table 366. India Anti-Infective Drugs Sales, by Type K Unit (2023-2028)
  • Table 367. India Anti-Infective Drugs Sales, by Indication K Unit (2023-2028)
  • Table 368. India Anti-Infective Drugs Sales, by Distribution Channel K Unit (2023-2028)
  • Table 369. South Korea Anti-Infective Drugs Sales, by Type K Unit (2023-2028)
  • Table 370. South Korea Anti-Infective Drugs Sales, by Indication K Unit (2023-2028)
  • Table 371. South Korea Anti-Infective Drugs Sales, by Distribution Channel K Unit (2023-2028)
  • Table 372. Taiwan Anti-Infective Drugs Sales, by Type K Unit (2023-2028)
  • Table 373. Taiwan Anti-Infective Drugs Sales, by Indication K Unit (2023-2028)
  • Table 374. Taiwan Anti-Infective Drugs Sales, by Distribution Channel K Unit (2023-2028)
  • Table 375. Australia Anti-Infective Drugs Sales, by Type K Unit (2023-2028)
  • Table 376. Australia Anti-Infective Drugs Sales, by Indication K Unit (2023-2028)
  • Table 377. Australia Anti-Infective Drugs Sales, by Distribution Channel K Unit (2023-2028)
  • Table 378. Rest of Asia-Pacific Anti-Infective Drugs Sales, by Type K Unit (2023-2028)
  • Table 379. Rest of Asia-Pacific Anti-Infective Drugs Sales, by Indication K Unit (2023-2028)
  • Table 380. Rest of Asia-Pacific Anti-Infective Drugs Sales, by Distribution Channel K Unit (2023-2028)
  • Table 381. Europe Anti-Infective Drugs Sales, by Country K Unit (2023-2028)
  • Table 382. Europe Anti-Infective Drugs Sales, by Type K Unit (2023-2028)
  • Table 383. Europe Anti-Infective Drugs Sales, by Indication K Unit (2023-2028)
  • Table 384. Europe Anti-Infective Drugs Sales, by Distribution Channel K Unit (2023-2028)
  • Table 385. Germany Anti-Infective Drugs Sales, by Type K Unit (2023-2028)
  • Table 386. Germany Anti-Infective Drugs Sales, by Indication K Unit (2023-2028)
  • Table 387. Germany Anti-Infective Drugs Sales, by Distribution Channel K Unit (2023-2028)
  • Table 388. France Anti-Infective Drugs Sales, by Type K Unit (2023-2028)
  • Table 389. France Anti-Infective Drugs Sales, by Indication K Unit (2023-2028)
  • Table 390. France Anti-Infective Drugs Sales, by Distribution Channel K Unit (2023-2028)
  • Table 391. Italy Anti-Infective Drugs Sales, by Type K Unit (2023-2028)
  • Table 392. Italy Anti-Infective Drugs Sales, by Indication K Unit (2023-2028)
  • Table 393. Italy Anti-Infective Drugs Sales, by Distribution Channel K Unit (2023-2028)
  • Table 394. United Kingdom Anti-Infective Drugs Sales, by Type K Unit (2023-2028)
  • Table 395. United Kingdom Anti-Infective Drugs Sales, by Indication K Unit (2023-2028)
  • Table 396. United Kingdom Anti-Infective Drugs Sales, by Distribution Channel K Unit (2023-2028)
  • Table 397. Netherlands Anti-Infective Drugs Sales, by Type K Unit (2023-2028)
  • Table 398. Netherlands Anti-Infective Drugs Sales, by Indication K Unit (2023-2028)
  • Table 399. Netherlands Anti-Infective Drugs Sales, by Distribution Channel K Unit (2023-2028)
  • Table 400. Rest of Europe Anti-Infective Drugs Sales, by Type K Unit (2023-2028)
  • Table 401. Rest of Europe Anti-Infective Drugs Sales, by Indication K Unit (2023-2028)
  • Table 402. Rest of Europe Anti-Infective Drugs Sales, by Distribution Channel K Unit (2023-2028)
  • Table 403. MEA Anti-Infective Drugs Sales, by Country K Unit (2023-2028)
  • Table 404. MEA Anti-Infective Drugs Sales, by Type K Unit (2023-2028)
  • Table 405. MEA Anti-Infective Drugs Sales, by Indication K Unit (2023-2028)
  • Table 406. MEA Anti-Infective Drugs Sales, by Distribution Channel K Unit (2023-2028)
  • Table 407. Middle East Anti-Infective Drugs Sales, by Type K Unit (2023-2028)
  • Table 408. Middle East Anti-Infective Drugs Sales, by Indication K Unit (2023-2028)
  • Table 409. Middle East Anti-Infective Drugs Sales, by Distribution Channel K Unit (2023-2028)
  • Table 410. Africa Anti-Infective Drugs Sales, by Type K Unit (2023-2028)
  • Table 411. Africa Anti-Infective Drugs Sales, by Indication K Unit (2023-2028)
  • Table 412. Africa Anti-Infective Drugs Sales, by Distribution Channel K Unit (2023-2028)
  • Table 413. North America Anti-Infective Drugs Sales, by Country K Unit (2023-2028)
  • Table 414. North America Anti-Infective Drugs Sales, by Type K Unit (2023-2028)
  • Table 415. North America Anti-Infective Drugs Sales, by Indication K Unit (2023-2028)
  • Table 416. North America Anti-Infective Drugs Sales, by Distribution Channel K Unit (2023-2028)
  • Table 417. United States Anti-Infective Drugs Sales, by Type K Unit (2023-2028)
  • Table 418. United States Anti-Infective Drugs Sales, by Indication K Unit (2023-2028)
  • Table 419. United States Anti-Infective Drugs Sales, by Distribution Channel K Unit (2023-2028)
  • Table 420. Canada Anti-Infective Drugs Sales, by Type K Unit (2023-2028)
  • Table 421. Canada Anti-Infective Drugs Sales, by Indication K Unit (2023-2028)
  • Table 422. Canada Anti-Infective Drugs Sales, by Distribution Channel K Unit (2023-2028)
  • Table 423. Mexico Anti-Infective Drugs Sales, by Type K Unit (2023-2028)
  • Table 424. Mexico Anti-Infective Drugs Sales, by Indication K Unit (2023-2028)
  • Table 425. Mexico Anti-Infective Drugs Sales, by Distribution Channel K Unit (2023-2028)
  • Table 426. Anti-Infective Drugs: by Type(USD/Units)
  • Table 427. Research Programs/Design for This Report
  • Table 428. Key Data Information from Secondary Sources
  • Table 429. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Anti-Infective Drugs: by Type USD Million (2017-2022)
  • Figure 5. Global Anti-Infective Drugs: by Indication USD Million (2017-2022)
  • Figure 6. Global Anti-Infective Drugs: by Distribution Channel USD Million (2017-2022)
  • Figure 7. South America Anti-Infective Drugs Share (%), by Country
  • Figure 8. Asia Pacific Anti-Infective Drugs Share (%), by Country
  • Figure 9. Europe Anti-Infective Drugs Share (%), by Country
  • Figure 10. MEA Anti-Infective Drugs Share (%), by Country
  • Figure 11. North America Anti-Infective Drugs Share (%), by Country
  • Figure 12. Global Anti-Infective Drugs: by Type K Unit (2017-2022)
  • Figure 13. Global Anti-Infective Drugs: by Indication K Unit (2017-2022)
  • Figure 14. Global Anti-Infective Drugs: by Distribution Channel K Unit (2017-2022)
  • Figure 15. South America Anti-Infective Drugs Share (%), by Country
  • Figure 16. Asia Pacific Anti-Infective Drugs Share (%), by Country
  • Figure 17. Europe Anti-Infective Drugs Share (%), by Country
  • Figure 18. MEA Anti-Infective Drugs Share (%), by Country
  • Figure 19. North America Anti-Infective Drugs Share (%), by Country
  • Figure 20. Global Anti-Infective Drugs: by Type USD/Units (2017-2022)
  • Figure 21. Global Anti-Infective Drugs share by Players 2022 (%)
  • Figure 22. Global Anti-Infective Drugs share by Players (Top 3) 2022(%)
  • Figure 23. Global Anti-Infective Drugs share by Players (Top 5) 2022(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 26. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2022
  • Figure 27. Merck (United States) Revenue, Net Income and Gross profit
  • Figure 28. Merck (United States) Revenue: by Geography 2022
  • Figure 29. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 30. Pfizer (United States) Revenue: by Geography 2022
  • Figure 31. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 32. Novartis AG (Switzerland) Revenue: by Geography 2022
  • Figure 33. Gilead Sciences (United States) Revenue, Net Income and Gross profit
  • Figure 34. Gilead Sciences (United States) Revenue: by Geography 2022
  • Figure 35. Abbott (United States) Revenue, Net Income and Gross profit
  • Figure 36. Abbott (United States) Revenue: by Geography 2022
  • Figure 37. Sanofi-Aventis (France) Revenue, Net Income and Gross profit
  • Figure 38. Sanofi-Aventis (France) Revenue: by Geography 2022
  • Figure 39. Bristol-Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 40. Bristol-Myers Squibb (United States) Revenue: by Geography 2022
  • Figure 41. Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 42. Johnson (United States) Revenue: by Geography 2022
  • Figure 43. Roche Pharma AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 44. Roche Pharma AG (Switzerland) Revenue: by Geography 2022
  • Figure 45. Nanosphere (United States) Revenue, Net Income and Gross profit
  • Figure 46. Nanosphere (United States) Revenue: by Geography 2022
  • Figure 47. Optimer Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 48. Optimer Pharmaceuticals (United States) Revenue: by Geography 2022
  • Figure 49. Basilea Pharmaceutica AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 50. Basilea Pharmaceutica AG (Switzerland) Revenue: by Geography 2022
  • Figure 51. Daiichi Sankyo (Japan) Revenue, Net Income and Gross profit
  • Figure 52. Daiichi Sankyo (Japan) Revenue: by Geography 2022
  • Figure 53. NanoViricides (United States) Revenue, Net Income and Gross profit
  • Figure 54. NanoViricides (United States) Revenue: by Geography 2022
  • Figure 55. Novabay Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 56. Novabay Pharmaceuticals (United States) Revenue: by Geography 2022
  • Figure 57. Global Anti-Infective Drugs: by Type USD Million (2023-2028)
  • Figure 58. Global Anti-Infective Drugs: by Indication USD Million (2023-2028)
  • Figure 59. Global Anti-Infective Drugs: by Distribution Channel USD Million (2023-2028)
  • Figure 60. South America Anti-Infective Drugs Share (%), by Country
  • Figure 61. Asia Pacific Anti-Infective Drugs Share (%), by Country
  • Figure 62. Europe Anti-Infective Drugs Share (%), by Country
  • Figure 63. MEA Anti-Infective Drugs Share (%), by Country
  • Figure 64. North America Anti-Infective Drugs Share (%), by Country
  • Figure 65. Global Anti-Infective Drugs: by Type K Unit (2023-2028)
  • Figure 66. Global Anti-Infective Drugs: by Indication K Unit (2023-2028)
  • Figure 67. Global Anti-Infective Drugs: by Distribution Channel K Unit (2023-2028)
  • Figure 68. South America Anti-Infective Drugs Share (%), by Country
  • Figure 69. Asia Pacific Anti-Infective Drugs Share (%), by Country
  • Figure 70. Europe Anti-Infective Drugs Share (%), by Country
  • Figure 71. MEA Anti-Infective Drugs Share (%), by Country
  • Figure 72. North America Anti-Infective Drugs Share (%), by Country
  • Figure 73. Global Anti-Infective Drugs: by Type USD/Units (2023-2028)
List of companies from research coverage that are profiled in the study
  • GlaxoSmithKline (United Kingdom)
  • Merck (United States)
  • Pfizer (United States)
  • Novartis AG (Switzerland)
  • Gilead Sciences (United States)
  • Abbott (United States)
  • Sanofi-Aventis (France)
  • Bristol-Myers Squibb (United States)
  • Johnson (United States)
  • Roche Pharma AG (Switzerland)
  • Nanosphere (United States)
  • Optimer Pharmaceuticals (United States)
  • Basilea Pharmaceutica AG (Switzerland)
  • Daiichi Sankyo (Japan)
  • NanoViricides (United States)
  • Novabay Pharmaceuticals (United States)
Additional players considered in the study are as follows:
Obetech , MerLion Pharma , Theravance
Select User Access Type

Key Highlights of Report


May 2023 229 Pages 62 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Anti-Infective Drugs Quantitative research analysis
Global Anti-Infective Drugs Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Anti-Infective Drugs market are GlaxoSmithKline (United Kingdom), Merck (United States), Pfizer (United States), Novartis AG (Switzerland), Gilead Sciences (United States), Abbott (United States), Sanofi-Aventis (France), Bristol-Myers Squibb (United States), Johnson (United States), Roche Pharma AG (Switzerland), Nanosphere (United States), Optimer Pharmaceuticals (United States), Basilea Pharmaceutica AG (Switzerland), Daiichi Sankyo (Japan), NanoViricides (United States) and Novabay Pharmaceuticals (United States), to name a few.
"Development In Drug Discovery Procedures " is seen as one of major influencing trends for Anti-Infective Drugs Market during projected period 2022-2028.
Anti-bacterial Drugs segment in Global market to hold robust market share owing to "Willingness towards Alternative Distribution and Dispensing of Antiviral Drugs ".

Know More About Global Anti-Infective Drugs Report?

Have a Query? Click Here

Other Related Reports

Doctor Bags Comprehensive Study by Type (Leather Bags, Cotton Bags, Canvas Bags, Nylon Bags, Other), Application (Women, Men), Distribution Chanel (Online, Offline) Players and Region - Global Market...
$ 3500
Phenylketonuria Drug Comprehensive Study by Type (Medications, Supplements , Others), Application (Household, Hospital, Others), Symtomps (Classic, Mild, Benign), Test (Diagnostic Test, Screening Tes...
$ 3500
Pneumonia Vaccine Comprehensive Study by Type (Pneumococcal Conjugate Vaccine (PCV13), Pneumococcal Polysaccharide Vaccine (PPSV23)), Patient Type (Pediatric Patients, Adult Patients), Distribution C...
$ 3350
Scopolamine Comprehensive Study by Type (Scopolamine Butylbromide, Scopolamine Hydrobromide, Scopolamine Base), Application (Oral, Injection, Patches), Form (Tablet, Syrup), Distribution Channel (Hos...
$ 3650
Pharmaceutical Lab Equipment Comprehensive Study by Type (General instrument, Analytical instrument, Specialty instrument, Others), Application (Research Institutions, Academic laboratory, Pharmaceut...
$ 3450
Interferon Comprehensive Study by Application (Oncology, Autoimmune Disorders, Diabetes, Inflammatory and Infectious Diseases, Neurological Diseases, Cardiovascular Diseases, Others), Drug Type (Inte...
$ 3750